KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Receivables - Other (2018 - 2024)

Historic Receivables - Other for Halozyme Therapeutics (HALO) over the last 7 years, with Q4 2024 value amounting to $20.3 million.

  • Halozyme Therapeutics' Receivables - Other rose 193000.0% to $20.3 million in Q4 2024 from the same period last year, while for Dec 2024 it was $20.3 million, marking a year-over-year increase of 193000.0%. This contributed to the annual value of $20.3 million for FY2024, which is 193000.0% up from last year.
  • According to the latest figures from Q4 2024, Halozyme Therapeutics' Receivables - Other is $20.3 million, which was up 193000.0% from $1.0 million recorded in Q4 2023.
  • Halozyme Therapeutics' 5-year Receivables - Other high stood at $69.2 million for Q3 2022, and its period low was $1.0 million during Q4 2023.
  • In the last 5 years, Halozyme Therapeutics' Receivables - Other had a median value of $22.4 million in 2023 and averaged $23.9 million.
  • As far as peak fluctuations go, Halozyme Therapeutics' Receivables - Other crashed by 9523.12% in 2023, and later surged by 193000.0% in 2024.
  • Over the past 5 years, Halozyme Therapeutics' Receivables - Other (Quarter) stood at $7.0 million in 2020, then skyrocketed by 328.57% to $30.0 million in 2021, then surged by 130.67% to $69.2 million in 2022, then crashed by 98.55% to $1.0 million in 2023, then soared by 1930.0% to $20.3 million in 2024.
  • Its last three reported values are $20.3 million in Q4 2024, $1.0 million for Q4 2023, and $3.3 million during Q3 2023.